These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35466606)

  • 21. A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.
    Poon SHL; Cheung JJ; Shih KC; Chan YK
    Rev Endocr Metab Disord; 2022 Jun; 23(3):541-567. PubMed ID: 35066781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statins in Graves Orbitopathy: A New Therapeutic Tool.
    Lanzolla G; Comi S; Cosentino G; Pakdel F; Marinò M
    Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S29-S39. PubMed ID: 38054983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid-associated ophthalmopathy in Iranian patients.
    Kashkouli MB; Jam S; Sabzvari D; Ketabi N; Azarinia S; SeyedAlinaghi S; Mofid A
    Acta Med Iran; 2011; 49(9):612-8. PubMed ID: 22052145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States.
    Wang Y; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Douglas RS
    Endocr Pract; 2022 Sep; 28(9):842-846. PubMed ID: 35714862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid eye disease in Eastern Province of Saudi Arabia: clinical profile and correlation with vitamin D deficiency.
    Alali M; Alkulaib NS; Alkhars A; Albadri K; Al Hassan S; Elewa M; Aldairi W; Alsaqer SK; Al-Abdulqader RA; Alhammad F
    Orbit; 2024 Feb; 43(1):28-32. PubMed ID: 36855900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease.
    Strianese D
    Curr Opin Ophthalmol; 2017 Sep; 28(5):505-513. PubMed ID: 28700384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monoclonal antibodies in the treatment of thyroid eye disease].
    Cheredanova VR; Poteshkin YE
    Vestn Oftalmol; 2021; 137(4):116-122. PubMed ID: 34410066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reactivation of Graves' Disease and Thyroid Eye Disease following COVID-19 Vaccination - A Case Report.
    Hung CW; Hung CH
    Ocul Immunol Inflamm; 2023 Aug; 31(6):1286-1290. PubMed ID: 36796028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum Vitamin D Deficiency Is an Independent Risk Factor for Thyroid Eye Disease.
    Heisel CJ; Riddering AL; Andrews CA; Kahana A
    Ophthalmic Plast Reconstr Surg; 2020; 36(1):17-20. PubMed ID: 31568022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective study of pediatric thyroid eye disease: the Asian experience.
    Sim B; Chng CL; Audrey C; Seah LL
    Orbit; 2022 Feb; 41(1):69-78. PubMed ID: 33059514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bilateral versus unilateral thyroid eye disease.
    Kashkouli MB; Kaghazkanani R; Heidari I; Ketabi N; Jam S; Azarnia S; Pakdel F
    Indian J Ophthalmol; 2011; 59(5):363-6. PubMed ID: 21836341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Graves' ophthalmopathy].
    Eckstein A; Dekowski D; Führer-Sakel D; Berchner-Pfannschmidt U; Esser J
    Ophthalmologe; 2016 Apr; 113(4):349-64; quiz 465-6. PubMed ID: 27059986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Biomarkers in Thyroid Eye Disease: A Literature Review.
    Ueland HO; Neset MT; Methlie P; Ueland GÅ; Pakdel F; Rødahl E
    Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S19-S28. PubMed ID: 38054982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroid eye disease: towards an evidence base for treatment in the 21st century.
    Gillespie EF; Smith TJ; Douglas RS
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):318-24. PubMed ID: 22354545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
    Wall JR; Lahooti H
    Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and natural history of Graves' orbitopathy in the XXI century.
    Piantanida E; Tanda ML; Lai A; Sassi L; Bartalena L
    J Endocrinol Invest; 2013 Jun; 36(6):444-9. PubMed ID: 23587873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
    Krassas GE
    Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for development or deterioration of Graves' ophthalmopathy.
    Stan MN; Bahn RS
    Thyroid; 2010 Jul; 20(7):777-83. PubMed ID: 20578901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of thyroid eye disease: quality-of-life questionnaire (TED-QOL) in Korean patients.
    Son BJ; Lee SY; Yoon JS
    Can J Ophthalmol; 2014 Apr; 49(2):167-73. PubMed ID: 24767223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.